FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 16 to 1 in favor of the albuterol/budesonide (PT027) from AstraZeneca (Nasdaq:AZN) to treat asthma in people at least 18 years old. The voting proposition asked whether the data supported a favorable benefit-risk assessment for various age groups. The advisory committee did not endorse albuterol/budesonide for patients 12…